Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rome – page 141

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rome at a glance
2 209
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 209 trials in Rome

Open in trial search

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALKYLATING AGENTS
  • Sponsor:Geron Corp.

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage IV

Not recruiting

Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Migraine

Not recruiting

Study on Lasmiditan for Treating Migraine in Children Aged 6 to 17

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Lasmiditan
  • Sponsor:Eli Lilly & Co.

Spinal muscular atrophy

Not recruiting

Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Trials

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Papillary serous endometrial carcinoma

Not recruiting

Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Atopic keratoconjunctivitis

Not recruiting

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorescein Sodium
  • Sponsor:Dompe' Farmaceutici S.p.A.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

  • Pulmonary function assessment
  • Disease exacerbation prevention
  • RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

  • Targeted molecular therapies
  • Combination treatment approaches
  • Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

  • Early disease intervention
  • Stroke treatment optimization
  • Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

  • Immune system modulation
  • Novel biological therapies
  • Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.